The Philly Special: 7pm dinner rez is the real winner
Why it matters: Eating earlier in the day supports your body's natural clock — boosting metabolism and improving sleep, experts say.
Driving the news: 7 o'clock dinners are our jam in Philly, with 19.6% of reservations booked in the 7-8pm hour compared to 17.5% for the rest of the country, per Resy data shared with Axios.
Some of us are late Birds, with a higher share of reservations booked after 9pm than those sleepyheads everywhere else.
Zoom out: Nationally, dinner times have shifted earlier since the pre-pandemic years.
What they're saying: If you have a later dinner, but eat the same amount, "that by itself leads to an increase in cravings, changes in appetite hormones and fewer calories burnt across the waking hours," Frank Scheer, Harvard Medical School professor and Medical Chronobiology Program director, tells Axios.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
7 hours ago
- Axios
RTP startup uses AI to fight health insurance denials
A Research Triangle Park startup wants to make appealing health insurance denials easier through a new artificial intelligence tool. Why it matters: A growing number of startups are turning to new AI tools to help patients navigate complex policies and byzantine processes to appeal insurance denials, according to NBC News. The number of prescription drug claims denied by insurance grew by 25% between 2016 and 2023, according to the New York Times. And in 2023, Affordable Care Act insurers denied 20% of claims, Axios reported. Driving the news: Enter Counterforce Health, a startup founded at the Frontier coworking campus in Research Triangle Park. The company's AI assistant drafts customized appeal letters that comb through a patient's policy, looking for the best line of defense, greatly reducing the amount of hours many patients spend drafting appeals. At the moment, few patients appeal denied claims at all, according to an analysis by KFF. Zoom in: Neal Shah, a former hedge fund manager turned startup founder, has been trying to change the health care industry he has found frustrating for years, through a succession of startups run by a handful of employees in RTP. Shah, who left his job on Wall Street to move back to North Carolina to take care of sick family members, is the founder of CareYaya, an online platform that helps connect people looking for at-home care workers with students studying health care. That platform has taken off in the past three years, growing from hundreds of workers based at Triangle-area universities to thousands across the country. Now, he's focused on expanding Counterforce Health, which he co-founded last year to provide free AI tools to patients and funding through several grant awards. The company's platform uses a variety of AI models to run its appeals process, pinging medical journals and insurance review commission data to make a case for why a patient's appeal should be granted. He views it as a way to counteract the algorithms that insurance companies use to deny claims. (Some insurance companies are currently being sued for using algorithms to deny claims, Axios previously reported.) What they're saying: "You end up spending hours and hours researching, fighting on the phone and just stressing the hell out," Shah told Axios about the current appeals process. "And many people will be too intimidated and scared to do that." In some ways, it's become a battle of AI versus AI in the insurance world, Shah added, and if the patient doesn't have a tool, "you lose." What's next: Right now, the Counterforce tools are free for patients and clinics to use. Some clinics are using the service, like Wilmington Health, to make it easier to draft appeals for its patients, and some pharmaceutical companies have begun reaching out to the team about the tools.
Yahoo
16 hours ago
- Yahoo
Breakthrough study finds deficiency of this common nutrient could contribute to Alzheimer's
A deficiency of the metal lithium in the body could be a key factor contributing to the development of dementia in Alzherimer's patients, a groundbreaking new study reveals. The decade-long research, published in the journal Nature, shows for the first time that lithium occurs naturally in the brain and maintains the normal function of all its major cell types, preventing nerves from degradation. Scientists from Harvard Medical School found that lithium loss in the human brain is one of the earliest changes leading to Alzheimer's, while in mice, a similar lithium depletion accelerated memory decline. A reduced lithium level was found in some cases due to the metal's impaired uptake and its binding to amyloid plaques, which are known to be smoking gun signs of Alzheimer's. Researchers also showed that a new type of lithium compound – lithium orotate – can avoid capture by amyloid plaques and restore memory in mice. In the study, scientists used an advanced type of mass spectroscopy chemical analysis method to measure trace levels of about 30 different metals in the brain and blood samples from a range of people, including cognitively healthy people, those in an early stage of dementia, and those with advanced Alzheimer's. The analysis revealed that lithium was the only metal with markedly different levels across groups, which also seemed to change at the earliest stages of memory loss. 'Lithium turns out to be like other nutrients we get from the environment, such as iron and vitamin C,' study senior author Bruce Yankner said. 'It's the first time anyone's shown that lithium exists at a natural level that's biologically meaningful without giving it as a drug,' Dr Yankner said. Although lithium compounds have been historically in use to treat a range of mental conditions like bipolar disorder and major depressive disorder, in these cases, they are given at much higher concentrations that could even be toxic to older people. Scientists have now found that lithium orotate is effective at one-thousandth this dose – enough to mimic the natural level of lithium in the brain. The latest findings with lithium orotate, however, needs to be confirmed in humans via clinical trials. Yet, researchers suspect that measuring lithium levels could help screen people for early Alzheimer's. The findings revise the theory of Alzheimer's disease, which affects nearly 400 million people worldwide, offering a new strategy for early diagnosis, prevention, and treatment. Decades of studies have shown that Alzheimer's disease involves an array of brain abnormalities, including clumps of the protein amyloid beta, tangles of the protein tau, and a loss of the brain's protective protein REST. However, these abnormalities have never fully explained the condition. For instance, it remains unclear why some people with Alzheimer's-like changes in the brain never go on to develop dementia or cognitive decline. Recent treatments developed to target amyloid beta plaques also don't seem to reverse memory loss, only modestly reducing the rate of cognitive decline. Now, scientists say lithium could be the critical missing link. 'The idea that lithium deficiency could be a cause of Alzheimer's disease is new and suggests a different therapeutic approach,' Dr Yankner said. 'You have to be careful about extrapolating from mouse models, and you never know until you try it in a controlled human clinical trial... But so far the results are very encouraging,' he added. Solve the daily Crossword
Yahoo
a day ago
- Yahoo
Breakthrough study finds deficiency of this common nutrient could contribute to Alzheimer's
A deficiency of the metal lithium in the body could be a key factor contributing to the development of dementia in Alzherimer's patients, a groundbreaking new study reveals. The decade-long research, published in the journal Nature, shows for the first time that lithium occurs naturally in the brain and maintains the normal function of all its major cell types, preventing nerves from degradation. Scientists from Harvard Medical School found that lithium loss in the human brain is one of the earliest changes leading to Alzheimer's, while in mice, a similar lithium depletion accelerated memory decline. A reduced lithium level was found in some cases due to the metal's impaired uptake and its binding to amyloid plaques, which are known to be smoking gun signs of Alzheimer's. Researchers also showed that a new type of lithium compound – lithium orotate – can avoid capture by amyloid plaques and restore memory in mice. In the study, scientists used an advanced type of mass spectroscopy chemical analysis method to measure trace levels of about 30 different metals in the brain and blood samples from a range of people, including cognitively healthy people, those in an early stage of dementia, and those with advanced Alzheimer's. The analysis revealed that lithium was the only metal with markedly different levels across groups, which also seemed to change at the earliest stages of memory loss. 'Lithium turns out to be like other nutrients we get from the environment, such as iron and vitamin C,' study senior author Bruce Yankner said. 'It's the first time anyone's shown that lithium exists at a natural level that's biologically meaningful without giving it as a drug,' Dr Yankner said. Although lithium compounds have been historically in use to treat a range of mental conditions like bipolar disorder and major depressive disorder, in these cases, they are given at much higher concentrations that could even be toxic to older people. Scientists have now found that lithium orotate is effective at one-thousandth this dose – enough to mimic the natural level of lithium in the brain. The latest findings with lithium orotate, however, needs to be confirmed in humans via clinical trials. Yet, researchers suspect that measuring lithium levels could help screen people for early Alzheimer's. The findings revise the theory of Alzheimer's disease, which affects nearly 400 million people worldwide, offering a new strategy for early diagnosis, prevention, and treatment. Decades of studies have shown that Alzheimer's disease involves an array of brain abnormalities, including clumps of the protein amyloid beta, tangles of the protein tau, and a loss of the brain's protective protein REST. However, these abnormalities have never fully explained the condition. For instance, it remains unclear why some people with Alzheimer's-like changes in the brain never go on to develop dementia or cognitive decline. Recent treatments developed to target amyloid beta plaques also don't seem to reverse memory loss, only modestly reducing the rate of cognitive decline. Now, scientists say lithium could be the critical missing link. 'The idea that lithium deficiency could be a cause of Alzheimer's disease is new and suggests a different therapeutic approach,' Dr Yankner said. 'You have to be careful about extrapolating from mouse models, and you never know until you try it in a controlled human clinical trial... But so far the results are very encouraging,' he added.
